Connor, Clark & Lunn Investment Management (CC&L)’s Supernus Pharmaceuticals SUPN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.87M | Sell |
122,793
-49,466
| -29% | -$1.56M | 0.01% | 657 |
|
|
2025
Q1 | $5.64M | Sell |
172,259
-29,310
| -15% | -$960K | 0.02% | 472 |
|
|
2024
Q4 | $7.29M | Sell |
201,569
-13,295
| -6% | -$481K | 0.03% | 390 |
|
|
2024
Q3 | $6.7M | Buy |
214,864
+127,420
| +146% | +$3.97M | 0.03% | 371 |
|
|
2024
Q2 | $2.34M | Buy |
87,444
+6,118
| +8% | +$164K | 0.01% | 609 |
|
|
2024
Q1 | $2.77M | Sell |
81,326
-22,671
| -22% | -$773K | 0.01% | 583 |
|
|
2023
Q4 | $3.01M | Buy |
103,997
+23,413
| +29% | +$678K | 0.01% | 565 |
|
|
2023
Q3 | $2.22M | Buy |
80,584
+24,365
| +43% | +$672K | 0.01% | 590 |
|
|
2023
Q2 | $1.69M | Buy |
56,219
+38,820
| +223% | +$1.17M | 0.01% | 651 |
|
|
2023
Q1 | $630K | Buy |
17,399
+3,940
| +29% | +$143K | ﹤0.01% | 819 |
|
|
2022
Q4 | $480K | Buy |
+13,459
| New | +$480K | ﹤0.01% | 872 |
|